chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I started to have a thickness in my throat. It wasn't exactly a sore throat, but I was clearing my throat a lot. Over the next few days, it turned into a cough. I took a rapid test on 03/02/2022 which came back negative. On 03/06/2022 I decided to go to pharmacy and take another COVID test and within two hours I received positive results. By 03/09/2022 I was experiencing a deeper cough that went into my chest. My nose was running backward going down my throat which caused even more coughing. These symptoms lasted until about 03/19/2022. I had not been feeling well. I had short of breath and fatigue. On 03/28/2022. I called my cardiologist for an annual checkup. They did an EKG which revealed by my heart was 170BPM at rest. I was diagnosed with A fib. I tested again on 04/18/2022 prior to a medical procedure and it was negative.
Initial and follow-up information has been received from a nurse and a physician concerning a 24 year old female assistant manager with a drug allergy to DILANTIN who was vaccinated intramuscularly into the left deltoid with the first dose of Gardasil (lot # 657617/0684U) on 29-MAY-2007. Concomitant therapy included LEXAPRO and YASMIN. On 02-JUN-2007, the patient "became sick" and went to the emergency room (ER). It was reported that she experienced headache, elevated liver enzymes, fever, severe back pain and a complete blood count that revealed infectious process. The nurse reported that the patient had a variety of tests performed on her in the ER, including a liver function test (LFT) which showed that the patient's liver enzymes were high. On 06-JUN-2007, the patient underwent the following laboratory test: Lyme disease enzyme-linked immunosorbent assay, negative; absolute blood band neutrophil count, 2.35 K/uL, blood lymphocyte count, 10%; mean corpuscular volume, 75 fL, serum Epstein-Barr viral capsid antigen immunoglobulin G antibody test, positive; serum alanine aminotransferase test (ALT (SGPT), 486 U/L; serum aspartate aminotransferase test (AST (SGOT), 311 U/L; mean corpuscular hemoglobin (MCH), 26 pg. On 06-JUN-2007, the patient also underwent an abdominal ultrasound. The physician's impression was that there was no evidence of gallstones or dilated intra-, extrahepatic biliary ducts and there was a stable splenic cyst present. On 11-JUN-2007, the patient underwent the following laboratory tests: MCH, 26 pg, WBC count, 10.8 x 10E3/uL; AST (SGOT), 49 IU/L; ALT (SGPT), 147 IU/L. The nurse reported that the patient was doing better, but her liver enzyme levels were still elevated. At the time of the report, the outcome of severe back pain, headache, infectious process and fever were unknown. The reporting physician considered elevated liver enzymes, severe back pain, headache, fever, and complete blood count revealing infectious process to be other important medical events. Additional information is not expected. All available medical records will be provided upon request.
After the vaccine client started c/o seeing spots, feeling dizzy and "almost passing out". She was given water to drink, a snack and to relax. She was not given any medications. Vital signs stable. No problems since except a sore arm.
She almost fainted.  BP dropped to 72/30. flushed pale skin. Pulse ox 96. Alert and felt dizzy throughout the stay. Paramedics arrived onsite and as requested by parents EMTs transported the client to the parents' vehicle.
Patient present with a rash covering entire body. Also c/o headache, body aches, sore throat, nasal congestion beginning 2.1.2021
Has not gotten the second dose more than 36 days after getting the first; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Has not gotten the second dose more than 36 days after getting the first) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-May-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Has not gotten the second dose more than 36 days after getting the first). On 07-May-2021, PRODUCT DOSE OMISSION ISSUE (Has not gotten the second dose more than 36 days after getting the first) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided. Treatment medications were unknown.   Most recent FOLLOW-UP information incorporated above includes: On 09-Sep-2021: Non significant follow-up appended.
Redness around injection site, 1 hive just above injection site. Patient was treated with Benadryl 12.5mg liquid orally and had an ice pack over reaction.   Patient was monitored in office for 15 minutes  at which point the redness had decreased significantly. The hive was still present. He did not have signs/symptoms of anaphylaxis at any point.
I got COVID-19. I had a fever, muscle aches, fatigue, and shortness of breath. I did talk to a doctor but they told me it was too late to take PAXLOVID. My symptoms lasted for a month if you are included the cough. I have been out for work for a week.
Within 6 hours of getting vaccines, this infant had a seizure, and respiratory failure which resulted in transport to the hospital by helicopter ambulance.  5/27/2008 MR received for DOS 5/01-06/08/2008 with D/C DX: Status epilepticus/Respiratory failure. Infant presented to ER in status epilepticus. During diaper change infant developed generalized seizure with tonic posturing and eye deviation followed by hypotonia.  Generalized seizure activity continued in ED. Intubated and sedated 2' to respiratory distress/failure. Nasoenteric tube for feeds.  Nystagmus c/w brainstem involvement. Developed aspiration pneumonia. Extensive w/u. Presumed mitochondrial disorder. D/C on GJ feeds.   6/03/2008 As of today, still in hospital. 9/08/2008 MR received for DOS 6/26-28/2008 with Final DX:  Cleft palate, Hypotonia, Aspiration pneumonia, Seizure Disorder, Attention to Gastrostomy tube. Pt presented with intermittant gagging and coughing since D/C. Prior to day of admission suctioning had been clear but today suctioning was formula from the mouth. GJ tube replaced
Pain in right arm around injection site Muscle pain and aches in joints overnight and throughout the next day
Mother reports in approx. one hour after immunization her son developed a red rash that started on trunk of body that through the day spread to neck and lower limbs. He also developed a "gulf ball size" lump at site of injection. No other symptoms. She did take to local clinic where she was instructed to give Benadryl. She reports, " They were not real concerned". Mother reports that with other immunizations that he usually developes a "lump but never a rash".
11:43 am: Client c/o "dizziness", no nausea or vomiting reported. Face became pale. BP=94/54, HR=65, RR=18, T=98.3 degrees F. Had client in supine position with legs elevated > 30 degrees. Hand were cool and clammy. Client ate breakfast prior to clinic. 11:55 am given approx. 1/2 cup of orange juice. Reported feeling better. Had client sit-up and sit in chair with head between legs. 12:01 pm BP=88/58, HR=65, RR=17. Color to face was appropriate and client reported no dizziness, nausea, vomiting. Lung sounds taken at 11:50 am were clear to all fields. 12:16 pm BP=98/58, HR=65, RR=18, T=97.6 degrees F. Client reported no dizziness and said felt better, client advised to seek ER if event occurs again. No previous Rx to vaccines reported.
pt. reports that at 9:00pm started to experience SOB, lip swelling,  as well as hives. went to ED. diagnosed as an allergic reaction. assessment: Hives/Rash chest, Left arm No indication for epinephrine Intervention: IV fluids for hydration, Solumedrol, Benadryl, Pepcid
I developed severe tinnitus (constant ringing in my ears) approximately 3 weeks after my last dose of the vaccine. Last dose was administered on December 21, 2021. The tinnitus was extremely disruptive; This is a spontaneous report received from a contactable reporter(s) (Pharmacist). The reporter is the patient.  A 45-year-old male patient received BNT162b2 (BNT162B2), on 22Dec2021 at 15:30 as dose 3 (booster), single (Lot number: FE3594) at the age of 44 years intramuscular, in right arm for covid-19 immunization. The patient's relevant medical history included: "Known allergies: Penicillin" (unspecified if ongoing). Concomitant medication(s) included: ATORVASTATIN. Vaccination history included: BNT162b2 (Dose Number: 2, Batch/Lot No: EL3248, Location of injection: Arm Right, Vaccine Administration Time: 12:00 PM, Route of Administration: Intramuscular), administration date: 16Mar2021, when the patient was 44-year-old, for Covid-19 immunization; BNT162b2 (Dose Number: 1, Batch/Lot No: EL3247, Location of injection: Arm Right, Vaccine Administration Time: 01:00 PM, Route of Administration: Intramuscular), administration date: 04Feb2021, when the patient was 44-year-old, for Covid-19 immunization. The following information was reported: TINNITUS (non-serious) with onset Jan2022, outcome "recovering", described as "I developed severe tinnitus (constant ringing in my ears) approximately 3 weeks after my last dose of the vaccine. Last dose was administered on December 21, 2021. The tinnitus was extremely disruptive". The event "i developed severe tinnitus (constant ringing in my ears) approximately 3 weeks after my last dose of the vaccine. last dose was administered on December 21, 2021. the tinnitus was extremely disruptive" required physician office visit. Therapeutic measures were taken as a result of tinnitus.  Additional information: patient took other medications in two weeks was atorvastatin, I developed severe tinnitus (constant ringing in my ears) approximately 3 weeks after my last dose of the vaccine. Last dose was administered on 21Dec2021. The tinnitus was extremely disruptive and debilitating. The tinnitus is slowly improving, 4 months later.
DATE OF BIRTH WRITTEN INCORRECTLY AND AGE WRITTEN AS 12 YEARS ON CONSENT SIGNED BY INDIVIDUAL PRESENTING AS MOTHER.  IDENTIFIED IN DATABSE WITH DATE OF BIRTH WHICH MAKES CHILD TOO YOUNG AND NOT ELIGIBLE FOR VACCINE IN 5/2021.
Patient received 0.25mL of Moderna Covid-19 Vaccine, Bivalent; No adverse event; This spontaneous case was reported by a nurse and describes the occurrence of UNDERDOSE (Patient received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On an unknown date, the patient experienced UNDERDOSE (Patient received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse event). At the time of the report, UNDERDOSE (Patient received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for UNDERDOSE (Patient received 0.25mL of Moderna Covid-19 Vaccine, Bivalent).    No concomitant medications were reported. It was unknown whether patient received any other vaccines in the 4 weeks prior to COVID-19.  Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 27-Dec-2022: Live Significant follow-up appended: Patient details (Age group) was added.
After 15 min patient had tingling in her left arm all the way down to her hand, then started to travel to left side of face.  5 min later tingling started to travel to her left leg.  Pulse ox- 96% HR 57.  1251- ED lead RN was then contacted to evaluate patient in the ED.
Starting January 4th, 2021, I noticed that I was itching on my chest and found a rash localized to my medial chest. The rash didn't appear to grow from the area. Later, on January 9th, I began to itch more on my lower back of neck and upper back and had someone take a look. They noted I had a rash in the upper back as well. Taking another claritin, tylenol, and using hydrocortisone cream has not helped with the rash.
Brief resolved unexplained event (BRUE) in infant  Healthy 2 m.o. Infant with fever and extreme fussiness following vaccines  yesterday, with brief cyanotic event of unknown origin on same day as vaccinations. Occurred while in  car seat and preceded by unusual-sounding breathing. . Suspect a transient airway event in the car seat, less likely  febrile seizure.
Patient states approximately 1 month after receiving the Seasonal Influenza vaccine she began loosing the hair on her scalp
Information has been received from a health professional concerning a 15 month old male who on 1/13/04 was vaccinated with the left thigh with a second dose of varicella virus vaccine live (lot # 646312/0829N). The patient's mother reported to the practice that on 1/25/04 the child developed about 20 vesicular lesions and no other symptoms. No product quality complaint was involved. Unspecified medical attention was sought. No other information was available. Follow up information indicated that the child developed a mild, scattered vesicular rash on 1/30/04. No labs or diagnostic tests were done and the patient recovered. Additional information is not expected.
Pt reported "heart racing" and she felt that her "head and face were hot" Vitals: 135/95, 80, 18 Pt stable and released from the vaccination site
patient got first dose of primary series and card just has booster dose but the patient thinks he was administered the bivalent; He received primary dose but medical records saying he received the booster; No adverse event; This spontaneous case was reported by a consumer and describes the occurrence of CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (patient got first dose of primary series and card just has booster dose but the patient thinks he was administered the bivalent), WRONG PRODUCT ADMINISTERED (He received primary dose but medical records saying he received the booster) and NO ADVERSE EVENT (No adverse event) in an adult male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 083b22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (patient got first dose of primary series and card just has booster dose but the patient thinks he was administered the bivalent), WRONG PRODUCT ADMINISTERED (He received primary dose but medical records saying he received the booster) and NO ADVERSE EVENT (No adverse event). At the time of the report, CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (patient got first dose of primary series and card just has booster dose but the patient thinks he was administered the bivalent), WRONG PRODUCT ADMINISTERED (He received primary dose but medical records saying he received the booster) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (patient got first dose of primary series and card just has booster dose but the patient thinks he was administered the bivalent) and WRONG PRODUCT ADMINISTERED (He received primary dose but medical records saying he received the booster).    No concomitant medication was reported.    Patient got first dose of primary series and card just has booster dose but the patient thoughts he was administered with the bivalent what he was saying he received primary dose but medical records saying he received the booster. No treatment information was reported.
I started to have severe back pain in my mid back area, and I started to feel hot and sweaty. I took a at home COVID-19 test in the evening that came back positive. I started to have chills, nasal congestion, and fatigue. My symptoms lasted for about 7 days.
pt states her left arm was sore about 6 hours after taking the vax but about 5 days later she woke up with a red shiny rash around the dorsal surface of her left arm.  It was about 4 x 6 inches in size, extremely itchy and warm to the touch.  She applied ice to it for about 4 days and took Benadryl which seems to help.  She says it is still pink but no longer is itching or hurting.
More than Half the vaccine dose leaked (Second Dose) per patient; More than Half the vaccine dose leaked (Second Dose) per patient; This spontaneous case was reported by a pharmacist and describes the occurrence of UNDERDOSE (More than Half the vaccine dose leaked (Second Dose) per patient) and DEVICE CONNECTION ISSUE (More than Half the vaccine dose leaked (Second Dose) per patient) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030B21A) for COVID-19 vaccination.     No Medical History information was reported.   In March 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Apr-2021 at 5:15 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 15-Apr-2021, the patient experienced DEVICE CONNECTION ISSUE (More than Half the vaccine dose leaked (Second Dose) per patient). On 15-Apr-2021 at 5:15 PM, the patient experienced UNDERDOSE (More than Half the vaccine dose leaked (Second Dose) per patient). On 15-Apr-2021 at 5:15 PM, UNDERDOSE (More than Half the vaccine dose leaked (Second Dose) per patient) had resolved. At the time of the report, DEVICE CONNECTION ISSUE (More than Half the vaccine dose leaked (Second Dose) per patient) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications were not reported. Per report, during vaccine administration, the needle dislocated from the syringe and one drip was lost on the floor. Therefore the patient requests for the dose to be repeated.   Most recent FOLLOW-UP information incorporated above includes: On 19-Apr-2021: Moderna vaccine first dose information updated.
After my 1st shot I developed a red itchy rash on my arm  and it was swollen, this lasted for 4 days.   After receiving my 2nd Moderna shot approximately 6 hours later I started having side effects.  They were a combination of chills, leg pains, leg and feet cramping, headaches, sore arm, nausea, dizziness, exhaustion, stomach pain.  I was unable to get out of bed for 2 days and the side effects lasted for 7 days that I was either in bed or on the couch, not the 24-48 hours that I was told I could expect.  I just called both my general physician and my GI doctor to alert them and they said to continue to treat the symptoms.
Patient skipped the check-in line at vaccine clinic and went straight to where the vaccinations were taking place. The clinic do not keep their covid-19 record cards on them, so at check-in is where we were verifying if they were eligible for a dose of Covid-19 vaccine. Patient told the nurse who was doing vaccinations that she had only had 2 doses and needed a  booster, when patient had actually received their booster on 11/18/2021 and was up-to-date with Covid vaccines at that time. Patient waited the 15 minute wait period after receiving an additional booster dose in error, and experienced no adverse events during this time.
My reactions with previous shots had gotten and I developed new ones. Lost 50 pounds, dizziness at least 10 times per day, ears began ringing periodically and got the chills often. Developed 2 new bumps on my penis and have muscle and stomach pains.
feels like he can't smell as well; Stuffy nose; Feeling horrible; arm is sore; Headache; Body aches; This spontaneous case was reported by a consumer and describes the occurrence of ANOSMIA (feels like he can't smell as well), NASAL CONGESTION (Stuffy nose), FEELING ABNORMAL (Feeling horrible), VACCINATION SITE PAIN (arm is sore) and HEADACHE (Headache) in a 28-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 019B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 21-Apr-2021, the patient experienced ANOSMIA (feels like he can't smell as well), NASAL CONGESTION (Stuffy nose), FEELING ABNORMAL (Feeling horrible), VACCINATION SITE PAIN (arm is sore), HEADACHE (Headache) and MYALGIA (Body aches). At the time of the report, ANOSMIA (feels like he can't smell as well), NASAL CONGESTION (Stuffy nose), FEELING ABNORMAL (Feeling horrible), VACCINATION SITE PAIN (arm is sore), HEADACHE (Headache) and MYALGIA (Body aches) outcome was unknown.            Patient's weight is given as 220. No concomitant medications were provided. Treatment details were not provided.   Most recent FOLLOW-UP information incorporated above includes: On 02-Aug-2021: Follow up contains seriousness information as non serious and denied for further follow up.; Sender's Comments: Based on current available information and the temporal association between product use and the start date of the events a causal relationship cannot be excluded.
Hives/rash on torso (back, sides, and hips). Itchy. Started two nights after 2nd dose and has continued (1 week after dose at time of filing). No reaction to 1st dose.
Pt states she awoke at 0600 01/05/2021 with right side facial paralysis Was seen by PA diagnosis with Bells Palsy was started on Prednisone 01/05/2021